Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of GTx-024 (Ostarine) for Muscle Wasting in NSCLC Patients on First-Line Platinum + Taxane Chemotherapy
2011-001791-19Phase 3Completed
- Sponsor
- GTx
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC), cancer anorexia-cachexia syndrome (CACS) and muscle atrophy comparing GTx-024 (Ostarine) with Placebo (2 arms). Primary endpoint: Physical function responder rate at Day 84. Started Jul 2011; status: completed.
02
Drugs
enobosarm
03
Conditions
non-small cell lung cancer (NSCLC)cancer anorexia-cachexia syndrome (CACS)muscle atrophy
Beyond the preview
Go deeper on 2011-001791-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001791-19.